Published in Am J Pathol on May 01, 2000
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Targeting the ubiquitin system in cancer therapy. Nature (2009) 3.27
Protean PTEN: form and function. Am J Hum Genet (2002) 2.43
Pten, a protean tumor suppressor. Am J Pathol (2001) 2.42
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A (2008) 1.78
Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer (2008) 1.66
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am (2008) 1.41
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol (2009) 1.40
Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell (2006) 1.38
Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.31
PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol (2015) 1.24
Protein kinases and phosphatases in the control of cell fate. Enzyme Res (2011) 1.23
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol (2005) 1.18
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell (2009) 1.11
Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY. Proc Natl Acad Sci U S A (2008) 1.08
Inhibition of neuronal phenotype by PTEN in PC12 cells. Proc Natl Acad Sci U S A (2004) 1.05
Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol (2002) 1.05
ATP modulates PTEN subcellular localization in multiple cancer cell lines. Hum Mol Genet (2008) 1.03
ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization. Cell Death Differ (2011) 1.02
PTEN: new insights into its regulation and function in skin cancer. J Invest Dermatol (2009) 0.98
Functional interaction of phosphatase and tensin homologue (PTEN) with the E3 ligase NEDD4-1 during neuronal response to zinc. J Biol Chem (2010) 0.96
Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci (2013) 0.96
Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther (2009) 0.95
Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders. Front Mol Neurosci (2014) 0.95
Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res (2006) 0.92
MicroRNA Role in Thyroid Cancer Development. J Thyroid Res (2011) 0.91
PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation. Carcinogenesis (2010) 0.91
Nuclear PTEN levels and G2 progression in melanoma cells. Melanoma Res (2009) 0.89
PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer. Am J Pathol (2011) 0.89
ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy (2015) 0.87
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Arch (2014) 0.87
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer (2012) 0.87
PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol (2003) 0.87
Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS One (2013) 0.86
Nongenomic Mechanisms of PTEN Regulation. Int J Cell Biol (2012) 0.86
The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne) (2016) 0.85
The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY) (2015) 0.84
Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. Cancer (2009) 0.84
Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma. Int J Mol Sci (2012) 0.84
Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab (2014) 0.83
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res (2014) 0.83
Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma. Br J Cancer (2001) 0.82
PTEN plasticity: how the taming of a lethal gene can go too far. Trends Cell Biol (2013) 0.82
Different conformations of phosphatase and tensin homolog, deleted on chromosome 10 (PTEN) protein within the nucleus and cytoplasm of neurons. PLoS One (2011) 0.81
PTEN gene: a model for genetic diseases in dermatology. ScientificWorldJournal (2012) 0.81
Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes. J Clin Endocrinol Metab (2012) 0.81
PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome. J Clin Endocrinol Metab (2012) 0.81
Study of PTEN subcellular localization. Methods (2014) 0.80
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol (2010) 0.80
Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer. Endocr Relat Cancer (2015) 0.79
Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility. Onco Targets Ther (2014) 0.79
CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration. Onco Targets Ther (2014) 0.78
Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology (2013) 0.78
New insight into the treatment of advanced differentiated thyroid cancer. J Thyroid Res (2012) 0.77
ΔNp63α represses nuclear translocation of PTEN by inhibition of NEDD4-1 in keratinocytes. Arch Dermatol Res (2013) 0.77
The role of podoplanin in the biology of differentiated thyroid cancers. PLoS One (2014) 0.76
Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. BMC Cancer (2015) 0.75
Multiple Meningiomas in a Patient with Cowden Syndrome. J Neurol Surg Rep (2016) 0.75
Importin-11 keeps PTEN safe from harm. J Cell Biol (2017) 0.75
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 13.98
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (1998) 6.62
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res (1997) 5.92
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39
Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol (1998) 3.51
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38
Functions of the MDM2 oncoprotein. Cell Mol Life Sci (1999) 3.35
The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res (1998) 3.15
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A (1998) 3.05
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer (1989) 2.52
The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res (1998) 2.32
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res (1999) 2.17
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res (1997) 2.06
Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res (1999) 1.86
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res (1999) 1.85
Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol (1998) 1.85
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res (1998) 1.83
Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene (1999) 1.72
Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol (1998) 1.63
Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer Res (1997) 1.13
Antigen retrieval, signal amplification and intensification in immunohistochemistry. Histochem Cell Biol (1996) 1.12
Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab (1998) 1.05
Cowden's disease (multiple hamartoma syndrome). Mayo Clin Proc (1981) 1.00
Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer (1998) 0.97
Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab (1998) 0.95
Cowden's disease: analysis of fourteen new cases. J Am Acad Dermatol (1984) 0.95
Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. Genes Chromosomes Cancer (1999) 0.94
Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. Hum Genet (1996) 0.92
Cowden's disease: a case report and review of the literature. J Dermatol Surg Oncol (1978) 0.85
Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int J Cancer (1998) 0.83
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst (2000) 16.92
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell (1992) 6.32
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature (1995) 6.16
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 5.86
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
A compendium of gene expression in normal human tissues. Physiol Genomics (2001) 5.66
Is secondary haemorrhage after tonsillectomy in adults an infective condition? Objective measures of infection in a prospective cohort. Clin Otolaryngol (2007) 5.45
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet (2001) 4.71
Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J (1992) 4.69
Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet (2000) 4.57
Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet (1997) 4.39
Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev (1993) 4.14
Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet (2005) 4.14
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2007) 3.89
Complete transformation by adenovirus 2 requires both E1A proteins. Cell (1984) 3.80
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet (2001) 3.58
Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology (2004) 3.54
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev (1994) 3.47
E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol (1996) 3.40
Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell (1990) 3.37
E2f3 is critical for normal cellular proliferation. Genes Dev (2000) 3.26
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet (1999) 3.22
Self-mutilation in clinical and general population samples: prevalence, correlates, and functions. Am J Orthopsychiatry (1998) 2.84
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet (2001) 2.77
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.75
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci U S A (2001) 2.65
Pneumococcal bacteraemia in two immunocompetent adults with otitis media and bronchitis. Lancet (1990) 2.59
Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature (1998) 2.57
Structural organization and expression of the mouse estrogen receptor. Mol Endocrinol (1987) 2.54
[Recommendations and unanswered questions in the diagnosis and treatment of thyroid nodules. Opinion of the Thyroid Section of the German Society for Endocrinology]. Dtsch Med Wochenschr (2005) 2.45
Hypoglycemia in hospitalized patients. Causes and outcomes. N Engl J Med (1986) 2.44
Micropuncture studies of the electrochemical aspects of fluid and electrolyte transport in individual seminiferous tubules, the epididymis and the vas deferens in rats. J Physiol (1971) 2.44
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol Cell Biol (1997) 2.33
Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet (2004) 2.29
Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol (2000) 2.27
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol Cell (2000) 2.21
Surgery for primary hyperparathyroidism 1962-1996: indications and outcomes. Med J Aust (1998) 2.17
E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev (2001) 2.16
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet (2000) 2.15
Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA (1999) 2.14
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet (1994) 2.14
Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A (1999) 2.10
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg (2000) 2.07
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res (1997) 2.06
Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet (2000) 2.05
Re-operative surgery for recurrent or persistent primary hyperparathyroidism. Aust N Z J Surg (1998) 2.05
Comparison of indirect and direct in-situ polymerase chain reaction in cell preparations and tissue sections. Detection of viral DNA, gene rearrangements and chromosomal translocations. Histochemistry (1993) 2.04
A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci U S A (2000) 2.02
Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res (2001) 2.02
Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). Nat Genet (1996) 2.01
PTEN mutations in gliomas and glioneuronal tumors. Oncogene (1998) 2.01
In vivo association of E2F and DP family proteins. Mol Cell Biol (1995) 1.99
E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc Natl Acad Sci U S A (1998) 1.99
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet (2004) 1.96
Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene (2010) 1.93
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res (2000) 1.90
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet (2001) 1.87
Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc Natl Acad Sci U S A (1998) 1.86
Molecular characterisation of a common SDHB deletion in paraganglioma patients. J Med Genet (2007) 1.86
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res (1999) 1.85
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet (2000) 1.84
Molecular identification of latent precancers in histologically normal endometrium. Cancer Res (2001) 1.84
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res (2000) 1.83
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81